-
-
[1]Keeffe EB, Dieterich DT, Han SH, et al.A treatment algorithm forthe management of chronic Hepatitis B Virue infection in the UnitedStated:An Update[J].Clin Gaetroenterol Hepatol, 2006, 4 (8) ∶936-962. [2]庄辉.美国2006年《慢性乙型肝炎病毒感染处理治疗规范》简介[J].中华肝脏病杂志, 2006, 14 (11) ∶871-874. [3]于乐成, 陈欣欣, 陈成伟, 等.美国慢性乙型肝炎病毒感染处理流程详细介绍[J].肝脏, 2006, 11 (6) ∶418-432. [4]陈成伟, 程明亮.解读《美国慢性乙型肝炎病毒感染处理流程》体会[J].ibid, 2006, 11 (6) ∶433-435. [5]邱德凯.有关最新慢性乙型肝炎抗病毒治疗文献读后感悟[J].ibid, 2006, 11 (6) ∶435. [6]姚碧莲, 张欣欣, 陈成伟, 等.慢性乙型肝炎抗病毒治疗规范进展[J].国际流行病学与传染病学杂志, 2007, 34 (2) ∶108-111. [7]Keeffe EB.Revised treatment algorithm for chronic hepatitis[J].GI&Hepatology News, 2007, 1 (1) ∶8. [8]Lok AS, McMahon BJ.AASLD practice guidelines:chronic hepatitisB[J].Hepatology, 2007, 45 (2) ∶507-539. [9]Lok AS, McMahon BJ.Correctin to AASLD guidelines on chronichepatitis B[J].ibid, 2007, 45 (6) ∶1347. [10]陈杰, 贾继东.2007年美国肝病学会慢性乙型肝炎防治指南推荐意见介绍[J].临床肝胆病杂志, 2007, 23 (2) ∶83-87. [11]罗生强, 张玲霞.2007年美国慢性乙型肝炎诊治推荐意见简介[J].中华肝脏病杂志, 2007, 15 (6) ∶472-480. [12]万谟彬, 于乐成, 陈成伟.AASLD慢性乙型肝炎临床指南 (2007) 精粹[J].肝脏, 2007, 12 (1) ∶46-51. [13] 任红.慢性乙型肝炎抗病治疗新策略——最新慢性乙型肝炎防治指南解读及体会[C].中华医学会第13次全国病毒性肝炎及肝脏病学术会议论文汇编, 2007, P29-32. [14] Ching-Lung Lai.Comparison of two new guidelines of treatmentfor chronic hepatitis B from the United statea[C].中华医学会第13次全国病毒性肝炎及肝脏病学术会议论文汇编, 2007, P45-46. [15]ACT-HBV Asia-Pacific steering committee members.Chronicchepatitie B:treatment alert[J].Liver Int, 2006, 26∶47-58. [16]马军.慢性乙型肝炎治疗共识修订 (2006) [J].胃肠病学与肝脏病学杂志, 2006, 15 (6) ∶543-549. [17]Prati D, Taioli E, Zanella A, et al.Updated definitions of healthyranges for serum alanine aminotransferase levels[J].Ann InternMed, 2002, 137 (1) ∶1-9. [18]Kim Hc, NamCN, Jee SH, et al.Normal serumALTconcentrationand risk of mortatity from liver diseases:Prospective cohot study[J].BMJ, 2004, 328 (4) ∶983-989. [19]魏倪, 杨栋, 杨方, 等.慢性乙型肝炎病毒携带者肝组织学特点与临床特征的关系[J].中华肝脏病杂志, 2007, 15 (5) ∶330-333. [20]范慧敏, 杨湛, 陈春燕, 等.乙型肝炎病毒携带者的肝脏病与特点[J].ibib, 2007, 15 (5) ∶334-337. [21]吴赤红, 斯崇文, 田庚善, 等.慢性乙型肝炎病毒携带者的病理与临床及预后分析[J].ibid, 2007, 15 (8) ∶577-581. [22]Lin CL, Liao LY, Liu CJ, et al.Hepatitie B Viral Factors inHBeAg-Negative carriers with persistently normal serum ALTLevels[J].Hepatology, 2007, 45 (5) ∶1193-1198. [23]李嘉, 赵桂鸣, 朱理珉.免疫耐受期和非活动性复制期乙型肝炎病毒感染者的肝脏病理与临床特征[J].中华肝脏病学杂志, 2007, 15 (5) ∶326-329. [24]蔡卫民, 郑敏, 翁红雷, 等.慢性肝炎患者血清纤维化指标的检测及其意义[J].中华内科杂志, 2001, 40 (7) ∶448-451. [25]蔡卫民, 孙永良, 张立煌, 等.肝纤维血清诊断指标的谱初步分析-附612例慢性肝病患者11项血清检测结果[J].中西医结合肝病杂志, 1995, 5 (1) ∶3-6. [26]Hoofnagle JH, Doo E, Liang TJ, et al.Management of hepatitis B:Summary of a clinical reseach workshop[J].Hepatology, 2007, 45 (4) ∶1056-1075. [27]Liaw YF.Towards a rational treatment strategy for chronic hepatitisB[J].Hep Intl, 2007, 1∶285-286。 [28] 王宁明, 王小红, 陈蒿.第42届欧洲肝病学会会议介绍[J].感染病杂志, 2007, 5 (2) ∶76-83. [29]Liaw YF.Rescue therapy for Lamivadine resesiestant chronic, hep-atitic Bwhen and how?[J].Hepatology, 2007, 45 (2) ∶266-267. [30]Rapti I, Dimou E, Mitsoula P, et al Adding-on versus switchingto adefovir therapy in lamivudine-resistant HBeAg-negatiue chron-ic hepatitis B[J].Hepatology, 2007, 45 (2) ∶307-313. [31]Yeo W, Mo FKF, Chan SL, et al.Hepatitis B viral load predictssurvival of HCC patients undergoing systemic chemotherapy[J].Hep-atology, 2007, 45 (6) ∶1382-1389. [32]Lok AS, Zoulim F, locarnin S, et al.Antiviral drug-resistantHBV:standardization of nomenclature and assays and recommenda-tions for management[J].Hepatology, 2007, 46 (1) ∶254-265. [33]Hatakeyama T, Noguchic, Hiraga N, et al.Serum HBV RNA in apredictor of early emergence of YMDD mutant im patients traded withlamivude[J].Hepatology, 2007, 45 (5) ∶1179-1186. [34]Shaheen AAM, Hyers RP.Diagnostic accuracy of the aspartate ami-notransferase-to-platelet ratio index for the prediction of hepatitis-C-related fibrosis:A systematic review[J].Hepatology, 2007, 46 (3) ∶912-921. [35]Lin CL, Liu CJ, Kao JH.Viral load in HbeAg negative carrierswith normal aminotransferase level[J].Hepatology, 2007, 46 (3) ∶947-949.
本文二维码
计量
- 文章访问数: 1969
- HTML全文浏览量: 3
- PDF下载量: 759
- 被引次数: 0